Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lapatinib

lapatinib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of lapatinib

48 trials tracked of lapatinib: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 608 citations.

48Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 13 Phase 2 30 Phase 1 4
  1. Phase 3 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting Completed · 608 cited
  2. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 338 cited
  3. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  4. Phase 4 A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval Completed · 3 cited
  5. Phase 3 Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Completed
  6. Phase 3 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed
Show 42 more trials
  1. Phase 3 Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer Completed
  2. Phase 3 Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer Completed
  3. Phase 3 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Completed
  4. Phase 3 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed
  5. Phase 3 Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study Completed
  6. Phase 3 A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer Completed
  7. Phase 3 Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer Completed
  8. Phase 3 ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Completed
  9. Phase 2 Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer Completed
  10. Phase 2 Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer Completed
  11. Phase 2 Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer Completed
  12. Phase 2 Lapatinib in Combination With Vinorelbine Completed
  13. Phase 2 Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma Completed
  14. Phase 2 Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Completed
  15. Phase 2 Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients Completed
  16. Phase 2 Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer Completed
  17. Phase 2 Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin Completed
  18. Phase 2 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed
  19. Phase 2 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab Completed
  20. Phase 2 Lapatinib and Bevacizumab for Metastatic Breast Cancer Completed
  21. Phase 2 Neoadjuvant GW572016 to Treat Breast Cancer Completed
  22. Phase 2 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Completed
  23. Phase 2 Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer Completed
  24. Phase 2 Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer Completed
  25. Phase 2 Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery Completed
  26. Phase 2 Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed
  27. Phase 2 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Completed
  28. Phase 2 Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Completed
  29. Phase 2 TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. Completed
  30. Phase 2 Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer Completed
  31. Phase 2 Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. Completed
  32. Phase 2 Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer Completed
  33. Phase 2 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed
  34. Phase 2 Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer Completed
  35. Phase 2 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed
  36. Phase 2 GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer Completed
  37. Phase 2 Lapatinib and Trastuzumab With or Without Endocrine Therapy Completed
  38. Phase 2 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed
  39. Phase 1 Concentration and Activity of Lapatinib in Vestibular Schwannomas Completed
  40. Phase 1 Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer Completed
  41. Phase 1 Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer Completed
  42. Phase 1 LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients Completed

Showing the 48 most-cited and recently-updated of 48 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN
OB/GYN & Women's Health Phase II
Phase II trial tests induction chemo with carboplatin, paclitaxel, lapatinib before transoral surgery in SCCHN Can a gentler, three-part treatment plan reduce side effects for head and neck cancer?
A single-arm phase II trial enrolled 40 previously untreated patients with SCCHN amenable to transoral surgery.
A three-part treatment plan for head and neck cancer aims to reduce harsh side effects by tailoring care based on surgery results.
CT.gov Mar 30, 2026